Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Down 21.5% in December

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totalling 116,200 shares, a decline of 21.5% from the December 15th total of 148,000 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average daily volume of 208,200 shares, the days-to-cover ratio is currently 0.6 days.

Vivos Therapeutics Stock Performance

Vivos Therapeutics stock opened at $5.12 on Thursday. The stock’s fifty day moving average is $4.00 and its two-hundred day moving average is $3.10. Vivos Therapeutics has a 1-year low of $1.91 and a 1-year high of $9.14.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on VVOS. Ascendiant Capital Markets reaffirmed a “buy” rating and issued a $6.60 price target on shares of Vivos Therapeutics in a research report on Wednesday, November 20th. Alliance Global Partners reduced their target price on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 19th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.